Adarza BioSystems

OverviewSuggest Edit

Founded in 2008, Adarza has developed a highly sensitive label-free diagnostic platform capable of measuring 100s more individual proteins than the best multiplex immunoassays available today. The Arrayed Imaging Reflectometry (AIR™) is a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid. Adarza delivers industry leading precision, accuracy, and robustness enabling highly multiplexed protein detection with high sensitivity and specificity. The company’s unique technology is flexible, data-rich, and easy to use, providing the only solution that spans the entire companion diagnostic life cycle from discovery to clinic, in both high-throughput core facilities as well as point of care (POC). Much like the first gene-chips enabled multiplexed genomics analysis, Adarza’s first-to-market high-multiplex and sensitivity antibody chips will fundamentally disrupt the field of proteomics research. Adarza is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at University of Rochester by Dr. Benjamin Miller, Adarza’s scientific founder.
TypePrivate
Founded2008
HQWest Henrietta, US
Websiteadarzabio.com

Latest Updates

Employees (est.) (Nov 2020)40(+3%)
Cybersecurity ratingCMore

Key People/Management at Adarza BioSystems

Bryan Witherbee

Bryan Witherbee

President and CEO
Christopher Striemer

Christopher Striemer

Vice President of Technology
Bob Crepin

Bob Crepin

Vice President of Manufacturing
Linda Meeh

Linda Meeh

Chief Commercial Officer
Jon Schmuke

Jon Schmuke

Chief Scientific Officer
Jason Mitchell

Jason Mitchell

Director of Engineering
Show more

Adarza BioSystems Office Locations

Adarza BioSystems has offices in West Henrietta and St. Peters
West Henrietta, US (HQ)
150 Lucius Gordon Dr
St. Peters, US
501 Pearl Dr
Show all (2)

Adarza BioSystems Financials and Metrics

Summary Metrics

Founding Date

2008

Adarza BioSystems total Funding

$31.1 m

Adarza BioSystems latest funding size

$17 m

Time since last funding

4 years ago

Adarza BioSystems investors

Adarza BioSystems's latest funding round in January 2017 was reported to be $17 m. In total, Adarza BioSystems has raised $31.1 m
Show all financial metrics

Adarza BioSystems Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Adarza BioSystems Online and Social Media Presence

Embed Graph

Adarza BioSystems Blogs

Using lasers to paint a high-definition picture of the body’s COVID-19 immune response

Biosensing firm Adarza BioSystems is getting ready to launch its Ziva protein detection platform, though a little later than originally expected and including a new application. In February, the firm raised $25 million in Series D funding and planned a summer release of its platform. But like many…

Adarza Shifts Focus to SARS-CoV-2 in Anticipation of Protein Biosensor Launch

Biosensing firm Adarza BioSystems is getting ready to launch its Ziva protein detection platform, though a little later than originally expected and including a new application. In February, the firm raised $25 million in Series D funding and planned a summer release of its platform. But like many…

Adarza’s Ziva provides window into immune response to COVID-19 and other pathogens

Adarza Biosystems Inc.’s Ziva platform can simultaneously detect hundreds of proteins, antibodies, or substrates from a single drop of blood, plasma or serum, providing insight into an individual’s immune response. That could be critical for both surveillance and diagnostic purposes as the nation pr…

St. Louis biotech startup raises $25M as it prepares for commercialization

Adarza BioSystems said the funding will help it prepare for commercialization of its ZIVA platform, a biological testing device designed to assist researchers with disease profiling and drug development.

Adarza raises $25 million, moves toward commercialization

Adarza, based in Maryland Heights, makes diagnostic systems for researchers and drug companies. It plans to launch its testing platform commercially in June.

Adarza BioSystems Raises $25 Million in Series D Funding to Launch Platform for Research and Drug Development

ST. LOUIS, MO (Feb. 4, 2020)—Biotech company Adarza BioSystems announced today that it has raised $25 million in a Series D round co-led by 3x5 Partners, based in Portland, Ore., and St. Louis-based Lightchain Capital, LLC, the family office of Scottrade founder Rodger Riney. Adarza plans to use the…

Adarza BioSystems Frequently Asked Questions

  • When was Adarza BioSystems founded?

    Adarza BioSystems was founded in 2008.

  • Who are Adarza BioSystems key executives?

    Adarza BioSystems's key executives are Bryan Witherbee, Christopher Striemer and Bob Crepin.

  • How many employees does Adarza BioSystems have?

    Adarza BioSystems has 40 employees.

  • Who are Adarza BioSystems competitors?

    Competitors of Adarza BioSystems include ArborMetrix, Wildflower Health and Kareo.

  • Where is Adarza BioSystems headquarters?

    Adarza BioSystems headquarters is located at 150 Lucius Gordon Dr, West Henrietta.

  • Where are Adarza BioSystems offices?

    Adarza BioSystems has offices in West Henrietta and St. Peters.

  • How many offices does Adarza BioSystems have?

    Adarza BioSystems has 2 offices.